Volume 194, number 12: Antibiotic Selection May Contribute to Increases in Macrolide-Resistant Treponema pallidum
14th Nov 2006, 00:59 GMT
To determine whether the 23S rRNA mutation that confers macrolide resistance is present in >1 Treponema pallidum strain, 58 isolates collected between 2001 and 2005 were screened for this mutation and for an unrelated sequence that distinguishes between strains. The odds of identifying a macrolide-resistant strain increased over time ([FORMULA]). In subjects who had received macrolides in the previous year, the relative risk of harboring a resistant strain was 2.2 (95% confidence interval, 1.1–4.4; [FORMULA]). The macrolide-resistant strains were not identical. These findings suggest that macrolide resistance may be increasing in multiple strains in response to antibiotic pressure.
Volume 194, number 12: Antibiotic Selection May Contribute to Increases in Macrolide-Resistant Treponema pallidum related news:
- In wake of deaths, FDA subjects antibiotic to new scrutiny — USATODAY.com Health - Top Stories
- FDA subjects antibiotic to new scrutiny in wake of reports of death and injury — WOODTV - Political News
- FDA subjects antibiotic to new scrutiny (Associated Press) — Yahoo! Health: Health News
- FDA Subjects Antibiotic to New Scrutiny — AP Top Health News At 10:37 a.m.
- FDA subjects antibiotic to new scrutiny (AP) — Yahoo! News: Health News
- MRSA: why Ireland can't go Dutch — The Irish Times' Health Top Stories
- Lab-on-a-chip could speed up treatment of drug-resistant pneumonia — EurekAlert! - Medicine and Health
- HIV/AIDS linked to extensively drug resistant TB — EurekAlert! - Breaking News
- WHO Concerned by Drug Resistant South African TB Strain — NPR Topics: Health & Science
- Ubuntu 7.04 Feisty Fawn List of Specifications — digg
Latest news from J Infect Dis Latest Issue:
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine
- Volume 194, number 12: Quantification of Viral Inactivation by Photochemical Treatment with Amotosalen and UV A Light, Using a Novel Polymerase Chain Reaction Inhibition Method with Preamplification
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138
- Volume 194, number 12: Evaluation of Purified Taenia solium Glycoproteins and Recombinant Antigens in the Serologic Detection of Human and Swine Cysticercosis
- Volume 194, number 12: Phase 1 Clinical Trials of the National Institutes of Health Vaccine Research Center HIV/AIDS Candidate Vaccines
- Volume 194, number 12: Is There a Safe Age for Vaccinating Infants with Tetravalent Rhesus-Human Reassortant Rotavirus Vaccine?
- Volume 194, number 12: Reply to Gargiullo et al.
- Volume 194, number 12: Is Panton-Valentine Leukocidin the Major Virulence Determinant in Community-Associated Methicillin-Resistant Staphylococcus aureus Disease?
- Volume 194, number 12: Human Cytolytic T Cell Recognition of Yersinia pestis Virulence Proteins That Target Innate Immune Responses